Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Intensity Therapeutics cash
Cash and short-term investments held at the end of each period.
Intensity Therapeutics's cash was $8.50M at Sep 30, 2026. For fiscal 2025 it was $11.90M, up 357.7% from the year before. The highest annual figure on record is $14.80M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.90M | +357.7% |
| FY2024 | Dec 31, 2024 | $2.60M | -82.4% |
| FY2023 | Dec 31, 2023 | $14.80M | +1028.0% |
| FY2022 | Dec 31, 2022 | $1.31M | -71.1% |
| FY2021 | Dec 31, 2021 | $4.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.50M | +19.7% |
| Q2 FY2026 | Jun 30, 2026 | $9.50M | +331.8% |
| Q1 FY2026 | Mar 31, 2026 | $10.20M | +1033.3% |
| Q4 FY2025 | Dec 31, 2025 | $11.90M | +357.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.10M | +155.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.20M | -65.1% |
| Q1 FY2025 | Mar 31, 2025 | $900.00K | -91.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.60M | -82.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.78M | -82.2% |
| Q2 FY2024 | Jun 30, 2024 | $6.30M | +4532.4% |
| Q1 FY2024 | Mar 31, 2024 | $10.50M | +22.7% |
| Q4 FY2023 | Dec 31, 2023 | $14.80M | +1028.0% |
| Q3 FY2023 | Sep 30, 2023 | $15.65M | +2146.6% |
| Q2 FY2023 | Jun 30, 2023 | $136.00K | -92.1% |
| Q1 FY2023 | Mar 31, 2023 | $8.56M | +88.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.31M | – |
| Q3 FY2022 | Sep 30, 2022 | $696.57K | – |
| Q2 FY2022 | Jun 30, 2022 | $1.72M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.54M | – |
See a number that looks wrong?